RxDoctor Payments Data

Xiaorong He, MD

Internal Medicine · Elmhurst, NYNPI 1962422972

Payments from drug & device makers

$12,521in general payments, 2019–2025

Across 562 payments — averaging $22.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Gilead$3K
  • Amgen$2K
  • AstraZeneca$1K
  • Johnson & Johnson$825
  • Amarin Pharma, Inc.$818
  • plus $869 from 8 others

What the payments were for

  • Food & beverage$12,491100%
  • Education$300%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,521 in reported general payments places this provider in the 90th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$148,955
Medicare patients
116
Services billed
3,136

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VascepaIcosapent Ethyl2,353$886,172
CreonLipase/Protease/Amylase622$764,969
Diclofenac Epolamine664$378,523
VemlidyTenofovir Alafenamide211$300,544
MyrbetriqMirabegron556$266,345
JardianceEmpagliflozin327$210,918
ProliaDenosumab100$172,414
FarxigaDapagliflozin Propanediol220$148,050
JanuviaSitagliptin Phosphate231$132,698
EliquisApixaban156$104,071
TradjentaLinagliptin184$100,314
XareltoRivaroxaban107$83,865
LinzessLinaclotide102$64,704
AbrysvoRsv Vacc, Pref A And Pref B/Pf244$64,048
Ursodiol910$51,407

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess, Namzaric, Restasis$3,646$893,787833 claims
GileadVemlidy$3,293$300,544211 claims
AstraZenecaFarxiga, Nexium, Symbicort$1,228$214,012477 claims
AmgenProlia$1,842$172,414100 claims
Johnson & JohnsonXarelto, Invokana$825$94,587126 claims
GSKShingrix, Trelegy Ellipta$53$44,966267 claims
NovartisEntresto$40$18,46935 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Elmhurst

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →